Random gene sets in predicting survival of patients with hepatocellular carcinoma

被引:18
作者
Itzel, Timo [1 ,2 ]
Spang, Rainer [3 ]
Maass, Thorsten [4 ]
Munker, Stefan [5 ]
Roessler, Stephanie [6 ]
Ebert, Matthias P. [7 ]
Schlitt, Hans J. [8 ]
Herr, Wolfgang [9 ]
Evert, Matthias [10 ]
Teuf, Andreas [1 ,2 ]
机构
[1] Heidelberg Univ, Med Fac Mannheim, Dept Med 2, Div Hepatol, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany
[2] Heidelberg Univ, Med Fac Mannheim, Dept Med 2, Div Clin Bioinformat, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany
[3] Univ Med Ctr, Dept Funct Genom, Stat Bioinformat, Regensburg, Germany
[4] Hepacult GmbH, Regensburg, Germany
[5] Ludwig Maximilians Univ Munchen, Grosshadem Univ Med Ctr, Dept Med 2, Munich, Germany
[6] Heidelberg Univ, Inst Pathol, Heidelberg, Germany
[7] Heidelberg Univ, Med Fac Mannheim, Dept Med 2, Heidelberg, Germany
[8] Univ Med Ctr, Dept Surg, Regensburg, Germany
[9] Univ Med Ctr, Dept Med 3, Regensburg, Germany
[10] Univ Regensburg, Dept Pathol, Regensburg, Germany
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 2019年 / 97卷 / 06期
关键词
HCC; Liver cancer; Prognostic; Signature; Gene set; Bioinformatics; Transcriptome; Profiling; Random; Swarm intelligence; Microarray; RNA Seq; CHEMOTHERAPY; HCC;
D O I
10.1007/s00109-019-01764-2
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Despite multiple publications, molecular signatures predicting the course of hepatocellular carcinoma (HCC) have not yet been integrated into clinical routine decision-making. Given the diversity of published signatures, optimal number, best combinations, and benefit of functional associations of genes in prognostic signatures remain to be defined. We investigated a vast number of randomly chosen gene sets (varying between 1 and 10,000 genes) to encompass the full range of prognostic gene sets on 242 transcriptomic profiles of patients with HCC. Depending on the selected size, 4.7 to 23.5% of all random gene sets exhibit prognostic potential by separating patient subgroups with significantly diverse survival. This was further substantiated by investigating gene sets and signaling pathways also resulting in a comparable high number of significantly prognostic gene sets. However, combining multiple random gene sets using swarm intelligence resulted in a significantly improved predictability for approximately 63% of all patients. In these patients, approx. 70% of all random 50-gene containing gene sets resulted in equal and stable prediction of survival. For all other patients, a reliable prediction seems highly unlikely for any selected gene set. Using a machine learning and independent validation approach, we demonstrated a high reliability of random gene sets and swarm intelligence in HCC prognosis. Ultimately, these findings were validated in two independent patient cohorts and independent technical platforms (microarray, RNASeq). In conclusion, we demonstrate that using swarm intelligence of multiple gene sets for prognosis prediction may not only be superior but also more robust for predictive purposes.Key messagesMolecular signatures predicting HCC have not yet been integrated into clinical routineDepending on the selected size, 4.7 to 23.5% of all random gene sets exhibit prognostic potential; independent of the technical platform (microarray, RNASeq)Using swarm intelligence resulted in a significantly improved predictabilityIn these patients, approx. 70% of all random 50-gene containing gene sets resulted in equal and stable prediction of survivalOverall, swarm intelligence is superior and more robust for predictive purposes in HCC
引用
收藏
页码:879 / 888
页数:10
相关论文
共 18 条
  • [1] Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer
    Ayers, M
    Symmans, WF
    Stec, J
    Damokosh, AI
    Clark, E
    Hess, K
    Lecocke, M
    Metivier, J
    Booser, D
    Ibrahim, N
    Valero, V
    Royce, M
    Arun, B
    Whitman, G
    Ross, J
    Sneige, N
    Hortobagyi, GN
    Pusztai, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) : 2284 - 2293
  • [2] Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
    Gerlinger, Marco
    Rowan, Andrew J.
    Horswell, Stuart
    Larkin, James
    Endesfelder, David
    Gronroos, Eva
    Martinez, Pierre
    Matthews, Nicholas
    Stewart, Aengus
    Tarpey, Patrick
    Varela, Ignacio
    Phillimore, Benjamin
    Begum, Sharmin
    McDonald, Neil Q.
    Butler, Adam
    Jones, David
    Raine, Keiran
    Latimer, Calli
    Santos, Claudio R.
    Nohadani, Mahrokh
    Eklund, Aron C.
    Spencer-Dene, Bradley
    Clark, Graham
    Pickering, Lisa
    Stamp, Gordon
    Gore, Martin
    Szallasi, Zoltan
    Downward, Julian
    Futreal, P. Andrew
    Swanton, Charles
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (10) : 883 - 892
  • [3] Ca H, 2012, ANTICANCER RES, V32, P1379
  • [4] Expectations, validity, and reality in omics
    Ioannidis, John P. A.
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2010, 63 (09) : 945 - 949
  • [5] Translating bioinformatics in oncology: guilt-by-profiling analysis and identification of KIF18B and CDCA3 as novel driver genes in carcinogenesis
    Itzel, Timo
    Scholz, Peter
    Maass, Thorsten
    Krupp, Markus
    Marquardt, Jens U.
    Strand, Susanne
    Becker, Diana
    Staib, Frank
    Binder, Harald
    Roessler, Stephanie
    Wang, Xin Wei
    Thorgeirsson, Snorri
    Mueller, Martina
    Galle, Peter R.
    Teufel, Andreas
    [J]. BIOINFORMATICS, 2015, 31 (02) : 216 - 224
  • [6] Expectations, validity, and reality in gene expression profiling
    Kim, Kyoungmi
    Zakharkin, Stanislav O.
    Allison, David B.
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2010, 63 (09) : 950 - 959
  • [7] A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells
    Lee, JS
    Heo, J
    Libbrecht, L
    Chu, IS
    Kaposi-Novak, P
    Calvisi, DF
    Mikaelyan, A
    Roberts, LR
    Demetris, AJ
    Sun, ZT
    Nevens, F
    Roskams, T
    Thorgeirsson, SS
    [J]. NATURE MEDICINE, 2006, 12 (04) : 410 - 416
  • [8] Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling
    Lee, JS
    Chu, IS
    Heo, J
    Calvisi, DF
    Sun, ZT
    Roskams, T
    Durnez, A
    Demetris, AJ
    Thorgeirsson, SS
    [J]. HEPATOLOGY, 2004, 40 (03) : 667 - 676
  • [9] Llovet JM., 2018, Nature Reviews Clinical Oncology, p41571
  • [10] Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): An emerging field for advanced technologies
    Marquardt, Jens U.
    Galle, Peter R.
    Teufel, Andreas
    [J]. JOURNAL OF HEPATOLOGY, 2012, 56 (01) : 267 - 275